PéptidosRD.COM

Single Peptides · Exact presentation

GHK-Cu · 50 mg Vial

GHK-Cu · 50 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.

Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.

GHK-Cu · 50 mg Vial — Nova Labs

Separate commercial record

Availability in the Dominican Republic

This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.

Dosing & Reconstitution Guide

For a 50 mg presentation, the reference concentration of 16.67 mg/mL mathematically corresponds to 2.999 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 16.67 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.1667 mg at this concentration.

Standard / Conservative Approach (3 mL = 16.67 mg/mL; 5 days/week)

The source chart summarizes “1 mg–2 mg” at “5 days/week” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Standard / Conservative Approach (3 mL = 16.67 mg/mL; 5 days/week)

Week/PhaseDose per InjectionUnits (per injection) (mL)
Weeks 1-41.0 mg (1000 mcg)6 units (0.06 mL)
Weeks 5-81.5 mg (1500 mcg)9 units (0.09 mL)
Weeks 9-12+2.0 mg (2000 mcg)12 units (0.12 mL)

Reconstitution Steps

For a 50 mg presentation, the reference concentration of 16.67 mg/mL mathematically corresponds to 2.999 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 16.67 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.1667 mg at this concentration.

Alternative Protocol (3 mL = 16.67 mg/mL; 3 times weekly)

The source chart summarizes “1 mg–2 mg” at “5 days/week” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Alternative Protocol (3 mL = 16.67 mg/mL; 3 times weekly)

Week/PhaseDose per InjectionUnits (per injection) (mL)
Weeks 1-12+2.0 mg (2000 mcg)12 units (0.12 mL)

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]

Allow vials to reach room temperature before opening to reduce condensation uptake.

Research Evidence Context

Much of this category relies on cellular or animal studies. Human evidence, when available, is often limited and does not establish guaranteed general benefits.

How This Works

It is studied in signaling pathways related to extracellular matrix, cell migration, inflammation, or tissue repair. Relevance depends on the compound and experimental model.

Potential Benefits & Observed Effects

Much of this category relies on cellular or animal studies. Human evidence, when available, is often limited and does not establish guaranteed general benefits.

Additional Technical and Protocol Sources

The source chart summarizes “1 mg–2 mg” at “5 days/week” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.

Source trail

Scientific references and source discovery

How PeptidosRD selects, separates, and reviews sources